Literature DB >> 19295407

Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor.

Anna Yemelyanova1, Russell Vang, Jeffrey D Seidman, Patti E Gravitt, Brigitte M Ronnett.   

Abstract

Determining the primary site of a uterine adenocarcinoma can be problematic in hysterectomy specimens due to the overlapping morphology of endocervical adenocarcinomas and endometrial carcinomas, particularly when both the corpus (usually lower uterine segment) and endocervix are involved and precursor lesions are lacking or difficult to distinguish from intramucosal spread of carcinoma from one site to the other. Both preferential extension of endocervical adenocarcinomas into the endometrium (rather than deep cervical stroma) and myometrial invasion derived from the endometrial component are rarely encountered; to our knowledge, these unusual patterns of spread have not been detailed in prior reports. Clinicopathologic features of 10 endocervical adenocarcinomas (9 pure, 1 adenosquamous) with prominent endometrial or endomyometrial involvement were evaluated. Tumors were analyzed for the presence of human papillomavirus (HPV) DNA and by immunohistochemistry for expression of p16 and hormone receptors. Six cases had limited amounts of tumor in the cervix proper, with depths of invasion no greater than 5 mm in 4 and only adenocarcinoma in situ in 2. Four cases had cervical stromal invasion of more than 5 mm but all of these had greater amounts of horizontal extension into endometrium or endomyometrium. Four tumors extended into endometrium only and 6 had myoinvasion associated with the endometrial component. Five tumors were originally diagnosed as primary endometrial carcinoma with either cervical extension or concurrent endocervical adenocarcinoma in situ. HPV DNA was detected in both the cervical and corpus components in all tumors and all exhibited diffuse/strong p16 expression and decreased or absent expression of hormone receptors. These ancillary techniques are useful for clarifying the origin of uterine adenocarcinomas when morphologic features and tumor location are equivocal. These cases illustrate that dominant uterine corpus involvement (endometrial or endomyometrial) by primary endocervical adenocarcinoma can lead to misclassification as primary endometrial adenocarcinoma with cervical extension (Fédération Internationale de Gynécologie et d'Obstétrique stage II), especially when endometrial extension of endocervical adenocarcinoma simulates complex atypical hyperplasia. A subset of misclassified endocervical adenocarcinomas may account for some HPV-positive uterine carcinomas reported as primary endometrial carcinomas.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19295407     DOI: 10.1097/PAS.0b013e3181971fdd

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  15 in total

1.  Human papillomavirus genotype-specific prevalence across the continuum of cervical neoplasia and cancer.

Authors:  Nancy E Joste; Brigitte M Ronnett; William C Hunt; Amanda Pearse; Erika Langsfeld; Thomas Leete; MaryAnn Jaramillo; Mark H Stoler; Philip E Castle; Cosette M Wheeler
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-11-02       Impact factor: 4.254

2.  A panel of 3 markers including p16, ProExC, or HPV ISH is optimal for distinguishing between primary endometrial and endocervical adenocarcinomas.

Authors:  Christina S Kong; Andrew H Beck; Teri A Longacre
Journal:  Am J Surg Pathol       Date:  2010-07       Impact factor: 6.394

3.  Diagnostic Algorithmic Proposal Based on Comprehensive Immunohistochemical Evaluation of 297 Invasive Endocervical Adenocarcinomas.

Authors:  Simona Stolnicu; Iulia Barsan; Lien Hoang; Prusha Patel; Luis Chiriboga; Cristina Terinte; Anna Pesci; Sarit Aviel-Ronen; Takako Kiyokawa; Isabel Alvarado-Cabrero; Malcolm C Pike; Esther Oliva; Kay J Park; Robert A Soslow
Journal:  Am J Surg Pathol       Date:  2018-08       Impact factor: 6.394

Review 4.  Endocervical adenocarcinoma: selected diagnostic challenges.

Authors:  Brigitte M Ronnett
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

Review 5.  How to approach the many faces of endometrioid carcinoma.

Authors:  Anais Malpica
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

6.  Secondary Involvement of the Adnexa and Uterine Corpus by Carcinomas of the Uterine Cervix: A Detailed Morphologic Description.

Authors:  Carolina Reyes; Rajmohan Murali; Kay J Park
Journal:  Int J Gynecol Pathol       Date:  2015-11       Impact factor: 2.762

7.  The usefulness of immunohistochemistry in tissue microarrays of Human Papillomavirus negative adenocarcinoma of the uterine cervix.

Authors:  Michael Odida; Belen Lloveras; Nuria Guimera; Elisabete Weiderpass
Journal:  BMC Res Notes       Date:  2010-03-03

8.  Cervical carcinomas with serous-like papillary and micropapillary components: illustrating the heterogeneity of primary cervical carcinomas.

Authors:  Richard Wing-Cheuk Wong; Joshua Hoi Yan Ng; Kam Chu Han; Yuen Ping Leung; Chiu Man Shek; Kin Nam Cheung; Carmen Ka Man Choi; Ka Yu Tse; Philip P C Ip
Journal:  Mod Pathol       Date:  2020-07-22       Impact factor: 7.842

9.  Detection of high-risk human papillomavirus subtypes in cervical glandular neoplasia by in situ hybridization.

Authors:  Zhang Sheng; Hiroshi Minato; Toshiyuki Sasagawa; Satoko Nakada; Eriko Kinoshita; Nozomu Kurose; Takayuki Nojima; Satoru Makinoda
Journal:  Int J Clin Exp Pathol       Date:  2013-09-15

10.  Diffusion-weighted magnetic resonance imaging to detect synchronous uterine endometrial and endocervical adenocarcinoma.

Authors:  Jesus Paul Carvalho; Publio Viana; Cristina Anton; Giovanni Favero; Alexandre Silva E Silva; Edmund Chada Baracat; Filomena Marino Carvalho
Journal:  Rare Tumors       Date:  2012-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.